ABVC
ABVC BioPharma, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2025(8Q snapshot) | 3Q | $2.97 | $1.07 | -64% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 3× in & out | Q4 2025 | Q2 2026 | → $1.09 | -63% |
| Millennium Management | Q4 2025 | Q1 2026 | → $1.63 | -44% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at ABVC BIOPHARMA, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jan 27, 2012 — the most recent Form 4 on file — not from today.
- Form 40001140361-12-003869Jan 27, 2012
- Form 40001140361-11-029881May 25, 2011
- Form 40001140361-11-026666May 11, 2011
- Form 40001140361-11-026658May 11, 2011
- Form 40001140361-11-026653May 11, 2011
- Form 40001140361-11-026646May 11, 2011
- Form 40001140361-10-033215Aug 13, 2010
- Form 4/Aamend0001140361-10-025839Jun 17, 2010
- Form 40001140361-10-024440Jun 7, 2010
- Form 40001140361-10-002048Jan 19, 2010
- Form 40001140361-09-029688Dec 18, 2009
- Form 40001140361-09-026149Nov 16, 2009
- Form 40001140361-09-022589Oct 5, 2009
- Form 40001140361-09-021546Sep 23, 2009
- Form 40001140361-09-021544Sep 23, 2009
Fundamentals
XBRL · ABVC BioPharma, Inc.Annual figures sourced directly from ABVC BioPharma, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for ABVC BIOPHARMA, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQUARTERLY REPORTMay 18, 2026
- 8-KCURRENT REPORTMar 27, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTMar 5, 2026
- 10-KANNUAL REPORTMar 3, 2026
- 10-Q/AAMENDMENT NO. 1 TO FORM 10-QMar 3, 2026
- 8-KCURRENT REPORTMar 3, 2026
- 8-K/AAMENDMENT NO. 1 TO FORM 8-KJan 16, 2026
- 8-KCURRENT REPORTNov 3, 2025
- 10-QQUARTERLY REPORTNov 3, 2025
- 8-KCURRENT REPORTOct 30, 2025
- 8-K/AAMENDMENT NO. 1 TO FORM 8-KSep 12, 2025
- 8-KCURRENT REPORTAug 14, 2025
- 10-QQUARTERLY REPORTAug 13, 2025
- 8-K/AAMENDMENT NO. 1 TO FORM 8-KJul 18, 2025
- 8-KCURRENT REPORTJun 4, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q4 2025 | Q2 2026 | $2.92 | $1.09 | -63% |
| Millennium Management | Q4 2025 | Q1 2026 | $2.92 | $1.63 | -44% |
| Renaissance Technologies | Q3 2025 | open | $2.97 | $1.07 | -64% |
| Citadel Advisors | Q1 2025 | Q2 2025 | $0.46 | $1.21 | +165% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $0.75 | $0.55 | -27% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.